Acronym
BioBoost
Code
F2021/IOF-StarTT/068
Duration
15 July 2021 → 30 June 2026
Funding
Regional and community funding: Industrial Research Fund
Promotor
Research disciplines
-
Medical and health sciences
- Biopharmaceuticals
- Cancer therapy
-
Engineering and technology
- Biomaterials
- Biomaterials engineering not elsewhere classified
Keywords
excipient
cancer
immunotherapy
Project description
Local administration of immunotherapeutics is burdened by low bio-availability. BioBoost is a technical solution that facilitates the interaction between these compounds and the immune cells of interest. In this way, BioBoost can be commercialized as a complementary technology for companies with a pipeline of novel immunotherapeutics.